Genetic testing can tell you what your patients can’t
New Updates to the GeneSight® Psychotropic Test
In March 2022, the GeneSight Psychotropic test was updated to include three additional medications – suvorexant (Belsomra®), lemborexant (Dayvigo®), and viloxazine (Qelbree®). Other updates include revised categorization rules for amitriptyline, removal of clinical consideration 4 from paroxetine when variation is present in HTR2A, and revised phenotype language for the HLA genes.
These exciting enhancements are designed to provide an even more complete picture of patients’ potential outcomes with certain medications prescribed to treat depression, anxiety, ADHD, and other psychiatric conditions.
Learn more by watching this short video.
In 2021, the GeneSight Psychotropic test was updated to include stimulants and non-stimulants approved for the treatment of ADHD, plus three additional genes – ADRA2A, CES1A1, and COMT*. Watch this short video to learn more about that update.
*COMT is provided for informational purposes.
The GeneSight test provides information about your patient that may help you avoid multiple medication trials.
The GeneSight Psychotropic test is a pharmacogenomic test that analyzes clinically important genetic variations which may impact how your patient metabolizes and responds to certain medications used to treat mental health conditions. The test is a powerful tool to augment your knowledge, experience and passion for your patients.
Tens of thousands of clinicians have ordered the GeneSight test for
patients and counting
A Comprehensive Report, Personalized for your Patient.
The GeneSight Psychotropic report provides information about which medications may require dose adjustments, be less likely to work, or have an increased risk of side effects based on your patient’s genetic information.
clinical studies published in peer-reviewed journals support the GeneSight test’s effectiveness.
In fact it’s the only psychiatric pharmacogenomic test backed by such extensive research.
Who Can Benefit from the GeneSight test?
Fewer than 50% of patients with depression respond to their first prescribed medication and with each failed medication trial, their treatment intolerance increases.1
Consider offering the GeneSight test to:
|New patients with a previous medication failure|
|Patients who are experiencing lower than desired medication response|
|Patients who are currently experiencing unwanted side effects|
|Elderly patients and patients with liver damage|
1 Rush AJ, et al. 2006 Am J Psychiatry
You or a member of your staff collect the patient’s DNA sample with a simple cheek swab OR your patient collects the sample at home using our patient collection kit
Your patient’s sample is sent to our lab for analysis. After the sample is received, result are typically available in about 2 days
Use the genetic insights from the GeneSight report to inform your treatment
Healthcare Provider Perspectives
See what happens when the GeneSight test becomes part of a clinician’s practice.
“The GeneSight test meets
“There is no other test
“The results speak
Watch and Learn
Our Learning Center provides educational information on a variety of topics related to pharmacogenomic testing and the GeneSight test.